Vimarsana
Biggest News Aggregation in the World

Page 2 - Established Brands News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Established Brands. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Established Brands Today - Breaking & Trending Today

Alexion Canada Appoints Karen Heim as New General Manager - Vimarsana News

Alexion Canada Appoints Karen Heim as New General Manager

Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024. In this role, Ms. Heim will lead the Canadian affiliate in its unwavering commitment to helping people affected by rare diseases live longer, healthier lives.

Source: yahoo.com
Safe Online Casinos – Top 10 Safe Casinos in 2024 - Vimarsana News

Safe Online Casinos – Top 10 Safe Casinos in 2024

Looking for safe and secure online casinos? We have reviewed the 10 safest casinos online available for US players to play for real money.

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Vimarsana News

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

Full year 2023 revenue of $6.3 billion, up 1% as-reported and 3% at constant currency Full year 2023 diluted earnings per share of $3.99 and non-GAAP Adjusted diluted earnings per share of...

Organon & Co (OGN) Reports Steady Growth Amidst Market Challenges - Vimarsana News

Organon & Co (OGN) Reports Steady Growth Amidst Market Challenges

Full Year Revenue Sees Modest Increase; Quarterly Dividend Declared

Source: yahoo.com
Why Is Organon Stock Trading Higher On Thursday? - Organon (NYSE:OGN) - Vimarsana News

Why Is Organon Stock Trading Higher On Thursday? - Organon (NYSE:OGN)

Organon exceeds Q4 2023 revenue expectations, reaching $1.6 billion. Women's Health thrives with 7% revenue increase, driven by Follistim AQ's 63% growth. Biosimilar revenue surges by 49%.